1383786-68-2

Basic information

• Product Name: methyl 2-(benzyloxy)-7-methoxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylate
• Synonyms: methyl 2-(benzyloxy)-7-methoxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylate
• CAS NO: 1383786-68-2
• Molecular Weight: 355.347
• Mol File: 1383786-68-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 2-(benzyloxy)-7-methoxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(benzyloxy)-7-methoxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylate(1383786-68-2)
• EPA Substance Registry System: methyl 2-(benzyloxy)-7-methoxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylate(1383786-68-2)

Safety Data

• Hazardous Substances Data: 1383786-68-2(Hazardous Substances Data)

Upstream product

• 67755-25-3 2-carboxymethyl-5-hydroxybenzoic acid 
• 1383786-67-1 methyl 2-{1-[(benzyloxy)amino]-3-methoxy-1,3-dioxopropan-2-yl}-5-methoxybenzoate 
• 255376-41-1 5-methoxy-2-methoxycarbonylmethyl-benzoic acid methyl ester 
• 1609575-79-2 C₁₃H₁₄O₇ 

Downstream Products

• 1383786-69-3 N-(4-fluorobenzyl)-2-(benzyloxy)-7-methoxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide 
• 1383785-73-6 N-(4-fluorobenzyl)-2-hydroxy-7-methoxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide 

Relevant articles and documents

Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2 H,4 H)-diones as human immunodeficiency virus type 1 integrase inhibitors

We report herein further insight into the biological activities displayed by a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs). Substitution of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains was previously shown by us to be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitors in the low nanomolar range associated with low micromolar anti-HIV activities were obtained. We investigated the influence of substitution at position 7 on biological activity. Introduction of electron-withdrawing functional groups such as the nitro moiety at position 7 led to a noticeable improvement of antiviral activity, down to low nanomolar anti-HIV potencies, with advantageous therapeutic indexes going close to those of the clinically used raltegravir and retained potencies against a panel of IN mutants.